Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
暂无分享,去创建一个
Michael L. Wang | C. Flowers | Shaojun Zhang | Guangchun Han | Linghua Wang | Jianhua Zhang | Xingzhi Song | K. Patel | P. Jain | R. Kanagal-Shamanna | L. Medeiros | Shaoying Li | C. Yin | Changying Jiang | K. Nomie | L. Fayad | J. Westin | S. Neelapu | S. Thirumurthi | O. Gonzalez-Pagan | S. Iyer | Ruiping Wang | H. Lee | G. Tang | A. Futreal | J. Romaguera | L. Nastoupil | N. Fowler | R. Nair | C. Ok | M. Badillo | Holly A. Hill | Guofan Xu | Wendy Chen | O. Oriabure | Richard Champlin | S. Iyer | D. Santos | Frederick Hagemeister | G. Gonzalez | Saira S. Ahmed | Yao Yixin | Pan Tinsu | H. Hill | Xingzhi Song | Wendy Y. Chen | Michael L. Wang | C. C. Yin | L. Jeffrey Medeiros | Graciela Nogueras Gonzalez | Hun Lee | Keyur P. Patel
[1] J. Kopczyński,et al. Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy , 2019, Scientific Reports.
[2] P. Jain,et al. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management , 2019, American journal of hematology.
[3] Michael L. Wang,et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma , 2019, Science Translational Medicine.
[4] W. Klapper,et al. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! , 2018, Blood.
[5] Michael L. Wang,et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis , 2018, Haematologica.
[6] S. Dawson,et al. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma , 2018, Nature Medicine.
[7] Michael L. Wang,et al. Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib , 2018, British journal of haematology.
[8] N. Lee,et al. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer , 2018, Nature Communications.
[9] Michael L. Wang,et al. Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL) , 2018, British journal of haematology.
[10] J. W. Hansen,et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. , 2017, Blood.
[11] F. Jardin,et al. Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells , 2017, Scientific Reports.
[12] L. Medeiros,et al. Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia. , 2017, Blood.
[13] Yu-Sun Chang,et al. Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall , 2017, Histopathology.
[14] E. Kimby,et al. 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau , 2016, British journal of haematology.
[15] A. Rosenwald,et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Klapper,et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.
[17] Su-Jin Shin,et al. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma , 2016, Histopathology.
[18] Michael L. Wang,et al. Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center , 2016, British journal of haematology.
[19] S. Kuhara,et al. Identification of miR-15b as a transformation-related factor in mantle cell lymphoma , 2015, International journal of oncology.
[20] F. Cavalli,et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.
[21] F. Jardin,et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index , 2014, Genes, chromosomes & cancer.
[22] Manel Juan,et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[23] E. Giné,et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[25] E. Giné,et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.
[26] M. Raffeld,et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index , 2012, Haematologica.
[27] W. Klapper,et al. Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.
[28] E. Kimby,et al. Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.
[29] R. Lai,et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis , 2011, Haematologica.
[30] B. Sander,et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma , 2011, Leukemia.
[31] R. Siebert,et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma , 2010, Genes, chromosomes & cancer.
[32] K. Karube,et al. Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki‐67 , 2010, Cancer science.
[33] J. Byrd,et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Prince,et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features , 2009, British journal of haematology.
[35] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[36] Adrian Wiestner,et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. , 2007, Blood.
[37] P. Dubus,et al. Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features , 2006, Histopathology.
[38] G. Brittinger,et al. Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients , 2006, Virchows Archiv.
[39] K. Franssila,et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. , 2003, European journal of cancer.
[40] C. D. Wu,et al. CD5- mantle cell lymphoma. , 2002, American journal of clinical pathology.
[41] B. Branger,et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype , 2001, Leukemia.
[42] W. Chan,et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.
[43] K. Young,et al. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients , 2017, The American journal of surgical pathology.
[44] Ryan D. Morin,et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.
[45] L. Medeiros,et al. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma , 2007, Modern Pathology.
[46] E. Campo,et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.